THR-149

Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)

Read more

 

THR-687

Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for the treatment of DME.

Read the full press release

 

Our mission

To prevent vision loss and address unmet medical needs in retinal disorders

Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Investors

Back of the eye disorders

At Oxurion we are dedicated to developing innovative treatments to preserve vision for patients with diseases affecting the back of the eye. The company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide.

Read more

Focus on patients

Pipeline

Intensive preclinical research, as well as our deep scientific knowledge of diseases affecting the back of the eye, has led to the development of disease-modifying therapies aimed to preserve patients’ vision. Our current pipeline of candidates is focused on new treatment approaches to diabetic eye disease and macular disorders.

Read more

Jetrea®

Investors

Oxurion is listed on Euronext Brussels under the symbol OXUR. Check our Investors pages to find more information about extraordinary and annual shareholders meetings and learn more about the full year results, half year results and business reviews by Oxurion, or download our publications and reports.

Read more

Advancing Science. Enhancing Vision.

Oxurion builds on a yearlong expertise and knowledge platform resulting from local and international scientific collaboration. In today’s rebranding, we further embrace our core expertise and evoke our aspirations for the future. As before, we are driven by the ambition to expand our activities, building on our past, into new areas.

We are advancing our pipeline of disease-modifying drug candidates to preserve vision for patients with back of the eye disorders and look forward to sharing the progress of our clinical programs.

- Patrik De Haes, MD, CEO of Oxurion

 

Stock Quote

3 reasons why we need to raise diabetic eye disease awareness

Read full story

Join forces to fight eye disease in developing countries

Read full story

9 striking facts about diabetic eye disease

Read full story

Careers

Oxurion employs 77 people worldwide, all are united by a shared goal: to make Oxurion a global leader in developing and commercializing innovative treatments for chronic eye disorders. Want to join us?

Visit our careers site

Partnerships

Oxurion relies on a network of experienced partners to bring the best possible eye care to patients across the globe. We are always open to new opportunities for partnership and collaboration for improving eye care.

Want to become a partner? Contact us!

Stay in touch

Be sure to check in regularly for the latest news about our our company, research & development activities and updates for investors or just subscribe to our mailing list to receive regular updates.

Read our latest news or Subscribe